In SURMOUNT-1, the tirzepatide trial, the highest dose averaged around 21% over 72 weeks (Jastreboff et al., 2022)
Purpose-built for physicians GLP-1RAs offer comparable weight loss to bariatric surgery with fewer side effects Key takeaways: Total body weight loss with tirzepatide 15 mg was similar to Roux-en-Y (15.18% vs
Crafted with clinically studied ingredients including probiotics, prebiotics, vitamins, and herbs, SymptoGuard supports digestion, energy, and overall well-being
For anything above 2.5mg per dose, switch to a higher concentration or a larger vial
These findings provide insight into retatrutides broader metabolic effects beyond glycemic control, informing future experimental and clinical research directions
tirzepatide targets GIP and GLP-1